A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
8 July, 2025
Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial
TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE
26 June, 2025
Cancer Survivor to Take on Fifth Kokoda trek to Support TROG
LATEST NEWS: 26 June 2025 He may be 76
